Hoechst Pakistan Limited

HPL

PK0021801011

Pharmaceuticals

End-of-day quote Pakistan S.E. Other stock markets 18:00:00 2024-05-23 EDT			5-day change	1st Jan Change
1,472 ^PKR	+7.50%		+2.68%	+22.71%

04-24	Hoechst Pakistan Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-18	Hoechst Pakistan Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Sanofi Aventis Pakistan Limited Announces Change of Company Secretary

August 29, 2012

Sanofi Aventis Pakistan Limited announced that Mr. Muhammad Irfan has ceased to be the Company Secretary of the company with effect from August 29, 2012 and Mr. Mohammad Ibadullah has been appointed as the Company Secretary in his place.

Latest news about Hoechst Pakistan Limited

Hoechst Pakistan Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	04-23	CI
Hoechst Pakistan Limited Reports Earnings Results for the Full Year Ended December 31, 2023	03-17	CI
Hoechst Pakistan Limited Announces Company Secretary Changes	11-01	CI
Hoechst Pakistan Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10-31	CI
Sanofi-aventis Pakistan Limited will Change its Name to Hoechst Pakistan Limited	23-09-05	CI
Sanofi-aventis Pakistan Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-28	CI
Sanofi-aventis Pakistan Limited Announces CEO Changes	23-06-13	CI
Sanofi-aventis Pakistan Limited Announces Retirement of Dr. Asim Jamal as Managing Director, Effective June 30, 2023	23-06-13	CI
Sanofi-aventis Pakistan Limited Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-29	CI
Sanofi-aventis Pakistan Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-05-02	CI
Sanofi Aventis Pakistan Limited Announces Change of Directors	23-05-01	CI
The Investor Consortium comprised of Packages Limited, IGI Investments Limited and Ali Gohar & Co. Ltd completed the acquisition of 52.87% stake in sanofi-aventis Pakistan Limited from Sanofi Foreign Participations B.V.	23-04-27	CI
Pakistan defers decision on drug price rise as pharma firms struggle	23-03-27	RE
Sanofi-aventis Pakistan Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-10-29	CI
Sanofi-aventis Pakistan Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-31	CI
Sanofi-aventis Pakistan Limited Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-29	CI
Sanofi-aventis Pakistan Limited Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-31	CI
Sanofi-aventis Pakistan Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-10-27	CI
Sanofi-Aventis Pakistan Limited Reports Earnings Results for the First Quarter Ended March 31, 2021	21-04-28	CI
Sanofi-Aventis Pakistan Limited Recommends Final Cash Dividend for the Year Ended December 31, 2020	21-03-02	CI
Sanofi-Aventis Pakistan Limited Reports Earnings Results for the Full Year Ended December 31, 2020	21-03-02	CI
Sanofi-Aventis Pakistan Limited Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-10-27	CI
Sanofi-Aventis Pakistan Limited Reports Earnings Results for the First Quarter Ended March 31, 2020	20-04-29	CI
Sanofi-Aventis Pakistan Limited Recommends Final Cash Dividend for the Year Ended December 31, 2019	20-03-03	CI
Sanofi-Aventis Pakistan Limited Reports Earnings Results for the Full Year Ended December 31, 2019	20-03-03	CI

Chart Hoechst Pakistan Limited

Duration

Period

More charts

Company Profile

Hoechst Pakistan Limited is a pharmaceutical company. The Company is engaged in the manufacturing, selling and trading of pharmaceutical and related products. The Company offers solutions for various therapeutic areas, such as antibiotics, cardiology, diabetes, pain and allergy and others. Its patient programs address unmet needs around access and education across Pakistan to support people with diabetes. It provides and delivers therapeutic solutions for cardiovascular diseases (CVDs) and works with healthcare professionals to impart awareness and knowledge to patients who are at risk of developing heart diseases. Its products include ampoules, vials, tablets and capsules, and oral liquids. Its brands include Flagyl, Clexane, No-Spa, Lantus, Amaryl, Claforan, Haemaccel, Enterogermina, Plavix and Selsun Blue. Selsun Blue helps treat and prevent dandruff symptoms by targeting dandruff from the source and thus soothes irritated scalp, fights itch and controls visible flakes.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HOECHST PAKISTAN LIMITED	+22.71%	47.45M
ELI LILLY AND COMPANY	+38.70%	728B
NOVO NORDISK A/S	+33.05%	603B
JOHNSON & JOHNSON	-6.13%	360B
MERCK & CO., INC.	+18.53%	332B
ABBVIE INC.	+0.99%	279B
ASTRAZENECA PLC	+16.00%	244B
NOVARTIS AG	+8.09%	207B
ROCHE HOLDING AG	-5.77%	205B
AMGEN INC.	+6.19%	164B